Clinical trials located in

Bobigny

Bobigny city is located in France. Currently, 17 clinical trials are being conducted in this city.

Bobigny, the préfecture of the Seine-Saint-Denis department in France, is a city rich in history and cultural diversity. Established as a small village in the Middle Ages, it has grown into a vibrant urban area. Notably, Bobigny was a center of resistance during World War II, with its railway station playing a tragic role in the deportation of Jews. The city is home to the Court of Appeals, highlighting its importance in the French judicial system. Bobigny also boasts a dynamic cultural scene, with the MC93 theater being a hub for contemporary performing arts.

  • CT-EU-00117059

    NCT04074096

    France
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Combining Azacitidine and Venetoclax for Higher-Risk Chronic Myelomonocytic Leukemia

    The AVENHIR study is an open-label clinical trial for patients with higher-risk chronic myelomonocytic leukemia, a type of blood cancer. This study will evaluate the effectiveness and safety of combining two drugs: Azacitidine and Venetoclax (also known as ABT-199). Azacitidine is a chemotherapy drug, while Venetoclax is a targeted therapy that works by blocking a specific protein in cancer cells.

    The main goals of the study are to determine the overall response rate to this drug combination, which means how many patients achieve complete remission, partial remission, or clinical benefit. The study will also closely monitor safety and any potential dose-limiting side effects during the first two treatment cycles.

    To be eligible for this study, patients must be newly diagnosed with higher-risk chronic myelomonocytic leukemia and have not received any prior treatment with hypomethylating agents like Azacitidine.

    France
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    AustriaBelgiumCzechiaFinlandFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing Itacitinib for Non-Severe Hemophagocytosis Lymphohistiocytosis treatment

    In this study, researchers are investigating the efficacy of a drug called Itacitinib in treating Hemophagocytic Lymphohistiocytosis (HLH), a rare disease characterized by the immune system attacking its own cells and tissues. Itacitinib is believed to be beneficial because it can disrupt the production of certain inflammatory chemicals in the body, potentially mitigating the harmful effects of HLH. Initially, this new treatment approach will be administered to participants with less severe forms of HLH. The primary objectives of the study are to assess the effectiveness of the medication after a 15-day period, determine the rate of complete response to the treatment, and identify any adverse effects unrelated to HLH. If the condition worsens while receiving Itacitinib, the drug will be discontinued, and patients will receive specific treatment for HLH.

    France
  • New potential drug evaluation in cholestatic pruritus

    This study aims to assess the effectiveness of the potential new drug-EP547 in alleviating cholestatic pruritus among individuals aged 18 to 80 with Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC). Inclusion criteria involve documented diagnoses of PBC or PSC, the presence of moderate to severe pruritus, and acceptance of specific anti-pruritic and anti-cholestatic medications. Exclusion criteria include pruritus unrelated to PBC or PSC, a history of liver transplantation, cirrhosis, alternative liver diseases, secondary sclerosing cholangitis, significant strictures or biliary stents, small bowel resection, and certain laboratory results indicating ineligibility.

    BelgiumFranceNetherlandsSpainUnited Kingdom
  • Evaluation of Namilumab in Chronic Pulmonary Sarcoidosis

    In this study, the focus is on investigating the potential benefits of the medication Namilumab for individuals with Chronic Pulmonary Sarcoidosis, a lung disease. Following the standard structure of medical studies, the new medicine is compared to a placebo. Monthly injections are administered to all participants for six months, but the allocation of the real medicine or the placebo remains undisclosed. For those who successfully complete the initial phase without significant issues, there is an option to extend their participation for an additional 28 weeks. During this extended period, the participants will continue to receive the actual medication, allowing for the monitoring of their progress and the assessment of the medicine’s impact over a more extended duration.

    BelgiumFranceGermanyNetherlandsUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Testing the safety and effectiveness of a new drug in the treatment of pulmonary fibrosis

    This study is testing a new drug called BMS-986278 for a lung disease called progressive pulmonary fibrosis. This condition causes the lungs to become increasingly scarred over time, making breathing difficult. Randomly assigned participants will receive either the real drug or a fake drug (placebo) that doesn’t work. No one will know who gets what, not even doctors. The goal is to see if this new drug helps slow the progression of the disease, prevent patients from having to be hospitalized and/or increase their chances of survival. These outcomes will be measured by tracking breathing tests, any sudden, serious worsening of the disease, any hospital stays related to lung disease, and any deaths from any cause.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Belimumab study for systemic sclerosis-lung disease

    This study evaluates belimumab’s efficacy and safety compared to a placebo in treating systemic sclerosis-associated interstitial lung disease (SSc-ILD). Approximately 300 participants will receive belimumab or a placebo alongside standard therapy. The main focus is on the drug’s impact on lung function, skin thickening, and symptoms affecting quality of life, like fatigue. The study aims to provide insights into better managing SSc-ILD, improving patient outcomes.

    BelgiumDenmarkFinlandFranceGermanyGreeceItalySpainUnited Kingdom
  • Baxdrostat in resistant hypertension: safety and efficacy study

    This study is testing a medication named baxdrostat in people who have high blood pressure that can’t be controlled with their current medication. The study will compare people who are given baxdrostat daily with people who are given a placebo. The goal of the study is to find out if baxdrostat is safe to take and if it helps lower blood pressure. The study will look at the effects of 1 mg and 2 mg doses of baxdrostat on blood pressure. The study will also look at whether Baxdrostat helps reach a blood pressure reading below 130 mmHg.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandSlovakiaSpainSwedenUnited Kingdom
  • Study of savolitinib and osimertinib Vs chemotherapy in advancing lung cancer

    This clinical trial will include approximately 324 people with a specific type of advanced lung cancer that has not improved with a specific treatment, osimertinib. People in this study will receive a combination of two drugs, savolitinib and osimertinib, or standard chemotherapy. The aim is to find out which treatment is more effective and safe. A person’s cancer will be monitored to see how it responds to treatment. If the cancer gets worse or the side effects become too much to bear, the person may stop participating in the study. The study will measure responses such as the number of people who see improvement in their cancer treatment, the time it takes for symptoms to get worse and the presence of drugs in the body.

    AustriaBelgiumBulgariaFranceGermanyGreeceItalyPolandSpainUnited Kingdom
  • Study of the effects of Durvalumab and Domvanalimab on non-small cell lung cancer

    This study looks at two drugs – Durvalumab and Domvanalimab – and how they may help people with a type of lung cancer that cannot be removed by surgery. These medicines are given to patients after special treatment combining chemotherapy and radiotherapy. The goal is to find out whether these drugs provide benefits and are safe to use. During the trial, patients will be given the real drug or a placebo (a substance that has no therapeutic effect), without knowing which one they will receive. The study will measure how long it takes for the disease to worsen, how long people live and how many people respond positively to treatment. This clinical trial is testing the effectiveness of Durvalumab and Domvanalimab – two drugs – in the treatment of stage III lung cancer that cannot be surgically removed. After undergoing chemotherapy and radiation therapy, participants will be given these drugs to assess their safety. The study is double-blind, meaning neither participants nor researchers know who is receiving the actual drug and who is receiving the placebo. The study will monitor whether the cancer gets worse and what the rate of positive reactions to the drugs is. A study is being conducted with two drugs, Durvalumab and Domvanalimab, for patients with advanced forms of lung cancer that cannot be treated with surgery. After undergoing combined chemotherapy and radiation therapy, participants receive these drugs. The study was designed so that neither the patient nor the doctor knew whether the correct drug or a placebo was being administered. The time until the disease worsens, how long participants live and the number of patients who see improvement with the drugs will be measured.

    BelgiumFranceGermanyGreeceHungaryItalyNorwayPolandRomaniaSpainUnited Kingdom
  • Testing a new trio of drugs for advanced and metastatic breast cancer

    This study, known as CAPItello-292, is testing a new combination of drugs to see if it can help treat advanced or spreading breast cancer. The drugs include one called capivasertib along with two others known as CDK4/6 inhibitors and another drug called fulvestrant. The study wants to see how well these work together and how safe they are. Firstly, they need to decide on the best dose of these drugs to use together. Then, the main part of the study will compare these drugs with the usual treatment – either of the CDK4/6 inhibitors with fulvestrant — to see which is better. Scientists will check the blood of the patients to see how much of the drugs are present. They also want to see how many people have side effects and how severe these are. Patients’ health will also be monitored, including heart tests, blood tests and checking vital signs. The ultimate goal is to see if this new treatment can slow down the growth of the cancer, or even shrink it. In simpler words, this is a study for people with a type of advanced breast cancer. It’s testing three drugs together — capivasertib, a CDK4/6 inhibitor, and fulvestrant. This study is made up of two parts. The first part is to decide on the right amount of these drugs to give at the same time. Then, they’ll test this against the usual treatment to see if it’s better. They’ll use blood tests to check how much of the drugs are in the body and will carefully watch for any side effects. They’ll also keep a close eye on people’s health overall. The main aim is to see if this new combination can stop the cancer from getting worse. The CAPItello-292 trial is aimed at patients with serious breast cancer that has started to spread. In this research, a new blend of three medicines, capivasertib, a CDK4/6 inhibitor, and fulvestrant, is being evaluated. First, researchers want to figure out the optimal dosing of these drugs when taken together. Then they’ll compare this combination to the standard treatment to see if it provides any additional benefits. They’ll take blood tests to track the amount of medication and continuously monitor for any potential side effects. The end goal is to see if this new drug mixture can slow or even decrease the growth of the cancer.

    BelgiumDenmarkFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in France:

.